ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

In Brief: Two Major Appointments Made At Fox Chase; HHS Names Task Force to Look At DRG Research Impact

April 20, 1984

In Brief: Elion Elected Member Of National Academy; Bleyer Heads M.D. Anderson Pediatrics

May 4, 1990

Kennedy Chooses Health/Education Chair Over Judiciary; No Major Changes In Senate Cancer Policies Expected

November 14, 1986

Phase II Study of Veliparib Improves PFS by 35 Percent

October 31, 2014

NCI Committee Attempts To Redesign Cooperative Groups Without Doing Harm

June 12, 1998

Novel Agents Promise Relief From Hematologic Side Effects

July 27, 2001